COMMUNIQUÉS West-GlobeNewswire

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
25/09/2026
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE [...]
CDT Equity Inc. Announces Reverse Stock Split
25/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of [...]
Teladoc Health Announces Chief Legal Officer Transition
25/09/2026
Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026 NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today [...]
Knowtex, the First Frontier AI Lab for Healthcare, Named Prime Awardee on VA's Nine-Figure Ambient Scribe Enterprise Contract
25/09/2026
One of two prime awardees on the $775.72 million multiple-award IDIQ, Knowtex is expanding AI that gives clinicians more time with Veterans. It's already live at 79 VA medical centers and more than 310 VA facilities [...]
INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
25/09/2026
SARASOTA, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of [...]
Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026
25/09/2026
NEW YORK and LONDON and LEAMINGTON, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the [...]
SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026
25/09/2026
IRVINE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide [...]
Kraig Labs’ Atlas Milestone Opens the Door to Potential Historic Spider Silk Advancements
25/09/2026
DENVER, Sept. 25, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- A completed library of living genetic building blocks positions Kraig Biocraft Laboratories (OTCQB: KBLB) to explore more than 200 potential [...]
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026
25/09/2026
Company to feature surgeon-led educational programming and technologies supporting liver surgery PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (Nasdaq: IART) will mark 20 years of CUSA® [...]
Fangzhou Releases 2026 Interim Report, Deepening "AI + Chronic Care" as a Lifetime Health Service Partner
25/09/2026
SHANGHAI, China, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has released its 2026 interim report, [...]
BioSyent Named as One of Canada’s Top Growing Companies 2026 by The Globe and Mail
25/09/2026
MISSISSAUGA, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named as one of Canada’s Top Growing Companies for 2026 by The [...]
Omotesando Helene Clinic and Maison Privé Clinic Sign Cooperation Agreement on International Medical Exchange and Patient Support
25/09/2026
Aiming to improve information sharing among medical staff and strengthen support systems for patients visiting from abroad TOKYO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Omotesando Helene Clinic (Japan) and Maison Privé [...]
Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
25/09/2026
Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform TORONTO and GERMANTOWN, Md., Sept. 25, 2026 (GLOBE [...]
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
25/09/2026
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to [...]
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
25/09/2026
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First Two Patients in [...]
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
25/09/2026
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM BRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech [...]
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
25/09/2026
Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days, [...]
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
25/09/2026
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée Trésorerie de 12,3 M€ au 30 juin 2026, multipliée par 2,4 par rapport au 31 décembre 2025 (5,1 M€), [...]
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
25/09/2026
Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May. Shareholders’ equity [...]

Pages